Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 11/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 9/20 | 0.37 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781697 | 1.00 | CA2 (0.39) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL36667 | 0.87 | CA2 (0.42) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL36666 | 0.87 | CA2 (0.42) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL2880829 | 0.87 | PLK1 (0.41) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL2880826 | 0.87 | PLK1 (0.41) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL28629847 | 0.82 | FAAH (0.42) | CA2ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL7789358 | 0.82 | SMPD1 (0.46) | — | |
| SCHEMBL7789356 | 0.82 | SMPD1 (0.46) | — | |
| SCHEMBL2582376 | 0.81 | ALDH1A1 (0.41) | TDP1 | |
| SCHEMBL2582375 | 0.81 | ALDH1A1 (0.41) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | claimed |
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | disclosed |
| US-6017675-A | POLYMERIZATION CATALYST | CIBA SPECIALTY CHEMIALS CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | QSOX1, HAO2, PAH | CA2 220/4885ATG4B 4855/4885PLA2G1B 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.